コンテンツへスキップ
Merck

スキップする

1345159

USP

Ioxaglic acid

United States Pharmacopeia (USP) Reference Standard

別名:

N-(2-Hydroxyethyl)-2,4,6-triiodo-5-{2-[2,4,6-triiodo-3-(N-methylacetamido)-5-(methylcarbamoyl)benzamido]acetamido}isophthalamic acid

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する
容量カタログ番号在庫状況単価
100 mg
カートの在庫状況を確認する
¥35,300

この商品について

実験式(ヒル表記法):
C24H21I6N5O8
CAS番号:
分子量:
1268.88
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

¥35,300


カートの在庫状況を確認する

バルクの問い合わせ
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします


grade

pharmaceutical primary standard

agency

USP

API family

ioxaglic acid

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Ic1c(c(c(c(c1C(=O)NCC(=O)Nc2c(c(c(c(c2I)C(=O)O)I)C(=O)NCCO)I)I)C(=O)NC)I)N(C)C(=O)C

InChI

1S/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43)

InChI key

TYYBFXNZMFNZJT-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ioxaglic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Ioxaglate Meglumine and Ioxaglate Sodium Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

類似品目との比較

比較内容をすべて表示

相違点を表示

1 of 1

当該品目
Y000014113450021344622
USP

USP

1345159

Ioxaglic acid

vibrant-m

Y0000141

Ioxaglic acid

USP

USP

1345002

Iotalamic acid

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

USP

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

ioxaglic acid

API family

ioxaglic acid

API family

iotalamic acid

API family

iohexol


Still not finding the right product?

Explore all of our products under Ioxaglic acid


保管分類

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする



Christian Delcour et al.
Cardiovascular and interventional radiology, 36(1), 237-238 (2012-06-15)
To test the compatibility of trisodium citrate, a catheter lock solution, with iodinated contrast medium. Iohexol, iobitridol, iodixanol, ioxaglate, ioxithalamate, iomeprol, and iopromide were tested. In all tests, 2 ml of contrast medium were mixed with 2 ml of trisodium citrate solution.
Laura Calvi et al.
Thyroid : official journal of the American Thyroid Association, 21(4), 443-449 (2011-03-10)
Thyrotoxicosis caused by destructive thyroiditis is self-limited and results from the subacute release of preformed thyroid hormone. Common etiologies include painful subacute thyroiditis and silent (painless) subacute thyroiditis (including postpartum thyroiditis, amiodarone-associated destructive thyroiditis, and lithium-associated thyroiditis). Thyrotoxicosis commonly evolves
G Kerckhofs et al.
European cells & materials, 25, 179-189 (2013-02-08)
We describe a non-destructive imaging method, named contrast-enhanced nanofocus X-ray computed tomography (CE-nanoCT), that permits simultaneously imaging and quantifying in 3D the (sub)tissue architecture and (biochemical) composition of cartilage and bone in small animal models at a novel contrast and



グローバルトレードアイテム番号

カタログ番号GTIN
1345159-100MG04061833860229

質問

レビュー

評価値なし

アクティブなフィルタ